PL3365685T3 - Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu - Google Patents

Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu

Info

Publication number
PL3365685T3
PL3365685T3 PL16791171T PL16791171T PL3365685T3 PL 3365685 T3 PL3365685 T3 PL 3365685T3 PL 16791171 T PL16791171 T PL 16791171T PL 16791171 T PL16791171 T PL 16791171T PL 3365685 T3 PL3365685 T3 PL 3365685T3
Authority
PL
Poland
Prior art keywords
kinogen
detection
large molecular
immunological test
dissolved large
Prior art date
Application number
PL16791171T
Other languages
English (en)
Inventor
Daniel J. Sexton
Ryan Faucette
Janja COSIC
Original Assignee
Dyax Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp. filed Critical Dyax Corp.
Publication of PL3365685T3 publication Critical patent/PL3365685T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL16791171T 2015-10-19 2016-10-19 Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu PL3365685T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562243505P 2015-10-19 2015-10-19
US201662335311P 2016-05-12 2016-05-12
PCT/US2016/057640 WO2017070170A1 (en) 2015-10-19 2016-10-19 Immunoassay to detect cleaved high molecular weight kininogen
EP16791171.8A EP3365685B1 (en) 2015-10-19 2016-10-19 Immunoassay to detect cleaved high molecular weight kininogen

Publications (1)

Publication Number Publication Date
PL3365685T3 true PL3365685T3 (pl) 2021-08-02

Family

ID=57233867

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20209278.9T PL3839514T3 (pl) 2015-10-19 2016-10-19 Oznaczanie immunologiczne do wykrywania rozszczepionego kininogenu wielkocząsteczkowego
PL16791171T PL3365685T3 (pl) 2015-10-19 2016-10-19 Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20209278.9T PL3839514T3 (pl) 2015-10-19 2016-10-19 Oznaczanie immunologiczne do wykrywania rozszczepionego kininogenu wielkocząsteczkowego

Country Status (17)

Country Link
US (2) US10914747B2 (pl)
EP (3) EP3365685B1 (pl)
JP (4) JP6903648B2 (pl)
KR (2) KR102966870B1 (pl)
CN (2) CN108291917B (pl)
AU (2) AU2016340826C1 (pl)
BR (1) BR112018007842A2 (pl)
CA (1) CA3002747A1 (pl)
CO (1) CO2018004289A2 (pl)
DK (1) DK3365685T3 (pl)
EA (1) EA201891002A1 (pl)
ES (2) ES2973301T3 (pl)
IL (3) IL258637B2 (pl)
MX (2) MX2018004763A (pl)
PL (2) PL3839514T3 (pl)
PT (1) PT3365685T (pl)
WO (1) WO2017070170A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
CN110658337B (zh) 2013-10-21 2023-06-16 武田药品工业株式会社 自身免疫性疾病的诊断和治疗
CN105873951A (zh) 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
EA201891002A1 (ru) 2015-10-19 2018-11-30 Дайэкс Корп. Иммунологический анализ для определения расщепленного высокомолекулярного кининогена
EP3694545A4 (en) * 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
US11976128B2 (en) 2018-03-23 2024-05-07 Board Of Regents, The University Of Texas System Human PD-L2 antibodies and methods of use therefor
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
EP3768723A4 (en) 2018-03-23 2021-12-29 Board of Regents, The University of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CA3104997A1 (en) * 2018-06-26 2020-01-02 Kyowa Kirin Co., Ltd. Antibody binding to chondroitin sulfate proteoglycan 5
AU2020392243A1 (en) 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU2548992A (en) 1991-08-13 1993-03-16 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH1084995A (ja) * 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) * 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) * 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008064336A2 (en) 2006-11-22 2008-05-29 Inivitrogen Corporation Autoimmune disease biomarkers
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009051259A1 (ja) 2007-10-18 2009-04-23 Miyazaki Prefectural Industrial Support Foundation 肝疾患診断用バイオマーカー
EP2215256A1 (en) 2007-10-22 2010-08-11 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
JP5348595B2 (ja) 2008-07-07 2013-11-20 日本臓器製薬株式会社 線維筋痛症の検査法
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE FROM PLASMA CALLICINE INHIBITORS
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
JP5937612B2 (ja) * 2010-12-02 2016-06-22 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 血液安定剤を含む採血用デバイス
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
WO2012170945A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
FR2983215B1 (fr) 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
EP4234583A3 (en) * 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
EP2950718A4 (en) * 2013-02-01 2016-09-21 Becton Dickinson Co BLUTSAMMELVORRICHTUNGEN WITH CONTACT PATH -HEMMENDEN ADDITIVES
CN105873951A (zh) 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
CN110658337B (zh) * 2013-10-21 2023-06-16 武田药品工业株式会社 自身免疫性疾病的诊断和治疗
ES3065185T3 (en) * 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
EA201891002A1 (ru) 2015-10-19 2018-11-30 Дайэкс Корп. Иммунологический анализ для определения расщепленного высокомолекулярного кининогена
WO2017106504A1 (en) 2015-12-15 2017-06-22 Dyax Corp. Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
EP4085266A1 (en) 2019-11-13 2022-11-09 EV-Technologies Spin-wave based magnetic and/or electro-magnetic field sensing device for dc, rf and millimeter-wave applications
EP4096687A4 (en) 2020-01-28 2024-02-28 Orgenesis Inc. Process and system for acellular therapy

Also Published As

Publication number Publication date
MX2018004763A (es) 2018-09-06
JP7640599B2 (ja) 2025-03-05
AU2016340826C1 (en) 2023-05-04
EA201891002A1 (ru) 2018-11-30
EP3365685B1 (en) 2020-11-25
JP2019502095A (ja) 2019-01-24
JP2021167824A (ja) 2021-10-21
IL312916B1 (en) 2026-03-01
CN108291917A (zh) 2018-07-17
US12493047B2 (en) 2025-12-09
JP7238027B2 (ja) 2023-03-13
EP4354146A2 (en) 2024-04-17
CN113655228B (zh) 2025-01-07
CN113655228A (zh) 2021-11-16
IL326475A (en) 2026-04-01
EP3365685A1 (en) 2018-08-29
IL312916A (en) 2024-07-01
KR20180093897A (ko) 2018-08-22
WO2017070170A1 (en) 2017-04-27
AU2023200462A1 (en) 2023-03-02
IL258637A (en) 2018-06-28
CA3002747A1 (en) 2017-04-27
EP3839514B1 (en) 2023-12-13
US10914747B2 (en) 2021-02-09
ES2857552T3 (es) 2021-09-29
IL312916B2 (en) 2026-07-01
MX2023005689A (es) 2023-05-29
EP4354146A3 (en) 2024-06-05
US20210270842A1 (en) 2021-09-02
PL3839514T3 (pl) 2024-06-10
US20180306807A1 (en) 2018-10-25
EP4354146B1 (en) 2026-04-15
CN108291917B (zh) 2021-08-27
JP6903648B2 (ja) 2021-07-14
KR102698737B1 (ko) 2024-08-27
PT3365685T (pt) 2021-03-01
DK3365685T3 (da) 2021-03-01
EP4354146C0 (en) 2026-04-15
KR20240133761A (ko) 2024-09-04
AU2016340826B2 (en) 2022-11-24
CO2018004289A2 (es) 2018-11-22
JP2025081553A (ja) 2025-05-27
ES2973301T3 (es) 2024-06-19
IL258637B2 (en) 2024-10-01
EP3839514A1 (en) 2021-06-23
AU2016340826A1 (en) 2018-04-26
JP2023078186A (ja) 2023-06-06
AU2023200462B2 (en) 2025-06-26
NZ741448A (en) 2023-10-27
IL258637B1 (en) 2024-06-01
BR112018007842A2 (pt) 2019-04-16
KR102966870B1 (ko) 2026-05-19

Similar Documents

Publication Publication Date Title
HUE053747T2 (hu) Eljárások AAV kimutatására
IL250521A0 (en) Method of malware detection and system thereof
LT3334841T (lt) Nukleorūgščių tyrimo būdai
EP3408402A4 (en) MAGNETIC ELECTROCHEMICAL DETECTION
EP3443066A4 (en) METHOD FOR EARLY DETECTING CANCER
DK3371619T3 (da) Detektering af et ubemandet luftfartøj
EP3317632A4 (en) LEAK DETECTION SYSTEM
IL250088B (en) Defect detection using structural information
EP3191599C0 (en) DETECTION OF MISFOLDED PROTEINS
IL249873A0 (en) Srm assays to chemotherapy targets
DE112016000423T8 (de) Abschnittslinienerkennungsvorrichtung
IL258637A (en) Immunoassay to detect cleaved high molecular weight kininogen
EP3318873A4 (en) TEST SYSTEM
IL262449B (en) Hybrid inspection system
FI20146115A7 (fi) Menetelmä kemikaalitestausta varten
DK3364189T3 (da) Immunkromatografisk teststykke
EP4027134C0 (en) INSPECTION SYSTEM
EP3141902C0 (en) URINE TESTING DEVICE
DK3511705T3 (da) Detekteringsanordning
DK3289363T3 (da) Specifik påvisning af clusterin isoformer
EP3598129A4 (en) SAMPLE DETECTION SYSTEM
PL3239588T3 (pl) Sposób wykrywania substancji
DK3391118T3 (da) Inspektionsanordning
BR112017007401A2 (pt) métodos de detecção específicos
EP3287522A4 (en) DETECTION OF FGFR2